BIIB EBITDA | BIOGEN INC.

BIOGEN INC. (BIIB) EBITDA

2026-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $204.40M.
2025-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $183.20M.
2024-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $147.50M.
2023-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $112.30M.

Complete source-backed ebitda history.

Available history: 2011-12-31 to 2022-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-03-31	Reported	(m)	(m)	$204.40M	(m)	(m)	$51.20M	$645.50M	$661.00M	(m)	$607.30M	$58.20M
2025-03-31	Reported	(m)	(m)	$183.20M	(m)	(m)	$37.10M	$259.30M	$629.30M	(m)	$572.50M	$70.70M
2024-03-31	Reported	(m)	(m)	$147.50M	(m)	(m)	$45.90M	$553.20M	$542.20M	(m)	$581.50M	$71.40M
2023-03-31	Reported	(m)	(m)	$112.30M	(m)	(m)	$66.60M	$455.30M	$662.80M	(m)	$605.00M	$50.70M
2022-03-31	Reported	$753.8M	(m)	(m)	$2.53B	29.77%	$57.90M	$161.80M	$753.90M	(m)	$634.90M	$125.60M
2021-12-31	Reported	$721.8M	(m)	(m)	$2.73B	26.40%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	$927.2M	(m)	(m)	$2.78B	33.37%	$42.00M*	$805.30M*	$511.80M	(m)	$654.10M	-$25.90M
2021-06-30	Reported	$602.9M	(m)	(m)	$2.78B	21.73%	$71.90M*	$1.23B*	$459.70M	(m)	$637.30M	-$409.10M
2021-03-31	Reported	$1.08B	(m)	(m)	$2.69B	39.96%	$92.60M	$769.00M	$478.10M	(m)	$595.00M	$44.20M
2020-12-31	Reported	-$220.9M	(m)	(m)	$2.85B	-7.74%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	$1.2B	(m)	(m)	$3.38B	35.58%	$84.10M*	$1.18B*	$449.10M	(m)	$573.10M	$240.80M
2020-06-30	Reported	$2.09B	(m)	(m)	$3.68B	56.70%	$105.00M*	$1.95B*	$411.10M	(m)	$555.10M	$446.10M
2020-03-31	Reported	$1.94B	(m)	(m)	$3.53B	54.88%	$149.70M	$1.47B	$454.30M	(m)	$570.10M	$292.00M
2019-12-31	Reported	$1.67B	(m)	(m)	$3.67B	45.62%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	$2.14B	(m)	(m)	$3.6B	59.33%	$90.10M*	$1.69B*	$430.00M	(m)	$554.50M	$211.30M
2019-06-30	Reported	$2.07B	(m)	(m)	$3.62B	57.31%	$186.90M*	$1.96B*	$476.30M	(m)	$587.60M	$248.10M
2019-03-31	Reported	$1.62B	(m)	(m)	$3.49B	46.53%	$127.10M	$1.46B	$602.00M	(m)	$567.70M	$422.50M
2018-12-31	Reported	$1.41B	(m)	(m)	$3.53B	39.89%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	$2.04B	(m)	(m)	$3.44B	59.44%	$163.20M*	$1.74B*	$460.80M	(m)	$497.70M	$369.80M
2018-06-30	Reported	$1.38B	(m)	(m)	$3.36B	41.25%	$186.80M*	$1.10B*	$421.00M	(m)	$516.20M	$263.70M
2018-03-31	Reported	$1.7B	(m)	(m)	$3.13B	54.41%	$194.70M	$1.46B	$446.00M	(m)	$501.30M	$322.50M
2017-12-31	Reported	$1.68B	(m)	(m)	$3.31B	50.66%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	$1.83B	(m)	(m)	$3.08B	59.50%	$229.10M*	$1.63B*	$370.00M	(m)	$433.40M	$383.80M
2017-06-30	Reported	$1.38B	(m)	(m)	$3.08B	44.95%	$197.70M*	$1.17B*	$366.20M	(m)	$429.80M	$269.60M
2017-03-31	Reported	$1.54B	(m)	(m)	$2.81B	54.67%	$210.00M	$235.20M	(m)	(m)	$498.70M	$239.20M
2016-12-31	Reported	$1.06B	(m)	(m)	$2.87B	37.08%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	$1.61B	(m)	(m)	$2.96B	54.32%	$170.30M*	$991.30M*	(m)	(m)	$462.70M	$337.00M
2016-06-30	Reported	$1.64B	(m)	(m)	$2.89B	56.52%	$136.80M*	$998.20M*	(m)	(m)	$492.40M	$353.60M
2016-03-31	Reported	$1.53B	(m)	(m)	$2.73B	56.04%	$126.90M	$1.02B	(m)	(m)	$497.30M	$356.40M
2015-12-31	Reported	$1.32B	(m)	(m)	$2.84B	46.65%	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	$1.52B	(m)	(m)	$2.78B	54.84%	$229.20M*	$895.40M*	(m)	(m)	$477.80M	$330.10M
2015-06-30	Reported	$1.38B	(m)	(m)	$2.59B	53.16%	$129.90M*	$1.05B*	(m)	(m)	$491.90M	$292.50M
2015-03-31	Reported	$1.27B	(m)	(m)	$2.56B	49.54%	$97.80M	$733.00M	(m)	(m)	$560.40M	$281.90M
2014-12-31	Reported	$1.32B	(m)	(m)	$2.64B	49.89%	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	$1.33B	(m)	(m)	$2.51B	52.88%	$62.55M*	$914.03M*	(m)	(m)	$570.44M	$274.77M
2014-06-30	Reported	$1.15B	(m)	(m)	$2.42B	47.61%	$64.00M*	$990.59M*	(m)	(m)	$576.62M	$268.52M
2014-03-31	Reported	$862.31M	(m)	(m)	$2.13B	40.49%	$54.31M	$104.63M	(m)	(m)	$511.67M	$178.41M
2013-12-31	Reported	$816.26M	(m)	(m)	$1.97B	41.52%	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	$832.01M	(m)	(m)	$1.83B	45.52%	$80.19M*	$671.92M*	(m)	(m)	$405.58M	$186.10M
2013-06-30	Reported	$790.95M	(m)	(m)	$1.72B	45.89%	$54.15M*	$625.21M*	(m)	(m)	$431.01M	$159.14M
2013-03-31	Reported	$607.98M	(m)	(m)	$1.42B	42.96%	$33.29M	$178.94M	(m)	$284.34M	$352.60M	$65.51M
2012-12-31	Reported	$542.38M	(m)	(m)	$1.42B	38.25%	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	$629.45M	(m)	(m)	$1.39B	45.43%	$58.06M*	$541.78M*	(m)	$304.22M	$299.63M	$131.04M
2012-06-30	Reported	$596.35M	(m)	(m)	$1.42B	41.97%	$72.90M*	$635.58M*	(m)	$329.56M	$301.77M	$121.02M
2012-03-31	Reported	$453.32M	(m)	(m)	$1.29B	35.09%	$54.55M	$194.63M	(m)	$355.96M	$300.09M	$82.15M
2011-12-31	Reported	$497.82M	(m)	(m)	$1.33B	37.52%	(m)	(m)	(m)	(m)	(m)	(m)
2011-09-30	Reported	$575.86M	(m)	(m)	$1.31B	43.96%	$51.35M*	$570.52M*	(m)	$301.39M	$261.40M	$127.10M
2011-06-30	Reported	$501.11M	(m)	(m)	$1.21B	41.46%	$54.09M*	$429.67M*	(m)	$285.64M	$266.30M	$95.04M
2011-03-31	Reported	$508.83M	(m)	(m)	$1.2B	42.28%	$32.14M	$253.58M	(m)	$293.63M	$244.52M	$117.47M
2010-12-31	Reported	$450.84M	(m)	(m)	$1.22B	36.98%	(m)	(m)	(m)	(m)	(m)	(m)
2010-09-30	Reported	$284.26M	(m)	(m)	$1.18B	24.18%	$38.96M*	$428.24M*	(m)	$319.05M	$244.16M	$75.01M
2010-06-30	Reported	$483.33M	(m)	(m)	$1.21B	39.86%	$47.05M*	$428.48M*	(m)	$331.68M	$262.32M	$102.24M
2010-03-31	Reported	$386.2M	(m)	(m)	$1.11B	34.83%	$38.21M	$336.89M	(m)	$307.03M	$248.66M	$75.31M
2009-12-31	Reported	$476.58M	(m)	(m)	$1.13B	42.29%	(m)	(m)	(m)	(m)	(m)	(m)
2009-09-30	Reported	$470.06M	(m)	(m)	$1.12B	41.95%	$38.41M*	$266.26M*	(m)	$304.06M	$226.75M	$113.94M
2009-06-30	Reported	$349.65M	(m)	(m)	$1.09B	31.98%	$34.68M*	$228.55M*	(m)	$416.45M	$220.83M	$92.71M
2009-03-31	Reported	$427.1M	(m)	(m)	$1.04B	41.21%	$37.04M	$300.75M	(m)	$279.48M	$221.83M	$65.22M
2008-12-31	Reported	$446.98M	(m)	(m)	$1.07B	41.82%	(m)	(m)	(m)	(m)	(m)	(m)
2008-09-30	Reported	$473.42M	(m)	(m)	$1.09B	43.32%	$379.05M*	$512.19M*	(m)	$268.80M	$232.82M	$114.34M
2008-06-30	Reported	(m)	$296.80M	(m)	(m)	(m)	(m)	(m)	(m)	$252.26M	$245.69M	$84.71M

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	(m)	$779.90M	(m)	(m)	$153.80M	$2.20B	$2.40B	(m)	$2.43B	$263.60M
2024-12-31	Reported	(m)	(m)	$673.20M	(m)	(m)	$153.70M	$2.88B	$2.31B	(m)	$2.40B	$273.80M
2023-12-31	Reported	(m)	(m)	$494.80M	(m)	(m)	$277.00M	$1.55B	$2.53B	(m)	$2.55B	$135.30M
2022-12-31	Reported	(m)	(m)	$518.40M	(m)	(m)	$240.30M	$1.38B	$2.28B	(m)	$2.40B	$632.80M
2021-12-31	Reported	$3.33B	(m)	(m)	$10.98B	30.31%	$258.10M	$3.64B	$2.11B	(m)	$2.67B	$52.50M
2020-12-31	Reported	$5.01B	(m)	(m)	$13.44B	37.24%	$424.80M	$4.23B	$1.81B	(m)	$2.50B	$992.30M
2019-12-31	Reported	$7.51B	(m)	(m)	$14.38B	52.21%	$514.50M	$7.08B	$1.96B	(m)	$2.37B	$1.16B
2018-12-31	Reported	$6.54B	(m)	(m)	$13.45B	48.61%	$770.60M	$6.19B	$1.82B	(m)	$2.11B	$1.43B
2017-12-31	Reported	$6.43B	(m)	(m)	$12.27B	52.36%	$867.40M	$4.55B	$1.63B	(m)	$1.93B	$2.46B
2016-12-31	Reported	$5.83B	(m)	(m)	$11.45B	50.96%	$616.10M	$4.59B	$1.48B	(m)	$1.95B	$1.24B
2015-12-31	Reported	$5.49B	(m)	(m)	$10.76B	51.02%	$643.00M	$3.92B	(m)	(m)	$2.11B	$1.16B
2014-12-31	Reported	$4.66B	(m)	(m)	$9.7B	48.03%	$287.80M	$2.94B	(m)	(m)	$2.23B	$989.90M
2013-12-31	Reported	$3.05B	(m)	(m)	$6.93B	43.96%	$246.30M	$2.35B	(m)	(m)	$1.71B	$601.00M
2012-12-31	Reported	$2.22B	(m)	(m)	$5.52B	40.27%	$254.55M	$1.88B	(m)	$1.33B	$1.28B	$470.55M
2011-12-31	Reported	$2.08B	(m)	(m)	$5.05B	41.27%	$208.02M	$1.73B	(m)	$1.22B	$1.06B	$444.53M
2010-12-31	Reported	$1.6B	(m)	(m)	$4.72B	34.02%	$173.06M	$1.62B	(m)	$1.25B	$1.03B	$331.33M
2009-12-31	Reported	$1.72B	(m)	(m)	$4.38B	39.37%	$165.65M	$1.07B	(m)	$1.28B	$911.03M	$355.62M
2008-12-31	Reported	$1.68B	(m)	(m)	$4.1B	40.89%	$275.95M	$1.56B	(m)	$1.07B	$925.30M	$365.78M
2007-12-31	Reported	$1.16B	(m)	(m)	$3.17B	36.58%	$284.11M	$1.02B	(m)	$925.16M	$776.10M	$272.42M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Revolution Medicines, Inc. (RVMD)	United States	$42.805B	-22.69
EXELIXIS, INC. (EXEL)	United States	$14.358B	16.15
NEUROCRINE BIOSCIENCES INC (NBIX)	United States	$14.131B	24.25
HALOZYME THERAPEUTICS, INC. (HALO)	United States	$13.083B	21.59
Twist Bioscience Corp (TWST)	United States	$11.540B	-47.21
BIO-TECHNE Corp (TECH)	United States	$11.379B	74.68
REPLIGEN CORP (RGEN)	United States	$10.755B	185.31
Krystal Biotech, Inc. (KRYS)	United States	$10.210B	45.56
Kymera Therapeutics, Inc. (KYMR)	United States	$9.631B	-31.69
ImmunityBio, Inc. (IBRX)	United States	$9.157B	-9.29